Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
LaFleur Minerals Acquires McKenzie East Gold Project Expanding Val-d'Or Gold Portfolio; Advances Aggressive Drilling at Swanson Gold Project
SAGA Metals Reports Assays from R-0027 to R-0029 with Intercepts Including 53.02% Fe2O3, 6.46% TiO2, 0.441% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
